SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Shareholders voted at the June 10, 2026 annual meeting on multiple matters including election of three directors (including John E. Jackson), advisory approval of named executive officer compensation, ratification of Ham, Langston & Brezina LLP as independent auditor, and approval of redomestication from Colorado to Texas.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final voting results from Rigetti Computing's 2026 Annual Meeting of Stockholders held on June 9, 2026, including the election of director Subodh Kulkarni as a Class I Director and ratification of BDO USA, P.C. as the independent registered public accounting firm. The disclosure directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Hudson Technologies' Annual Meeting of Shareholders held on June 10, 2026. The filing presents detailed vote tallies for three matters: (i) election of four directors (Loan N. Mansy, Richard Parrillo, Eric A. Prouty, and Alan Sheriff), (ii) non-binding advisory approval of named executive officer compensation, and (iii) ratification of BDO USA, P.C. as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Bluerock Homes Trust's annual meeting of stockholders held on June 10, 2026, including the election of five directors and ratification of Grant Thornton LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content, which is the standard disclosure required under Item 5.07 for shareholder meeting outcomes.
View raw filing on EDGAR →Caterpillar held its Annual Shareholders Meeting on June 10, 2026, with voting results on four proposals: election of all ten directors, ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and a shareholder proposal on written consent rights. The filing discloses complete vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Tvardi Therapeutics' Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class II directors (Imran Alibhai, Cynthia Smith, and Sujal Shah), advisory approval of executive compensation, frequency of compensation votes, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →TELA Bio held its Annual Meeting of Stockholders on June 11, 2026, with voting results on four proposals: election of Class I directors (Capper, Rocchio, Plovanic), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a 3.5 million share increase to the 2019 Equity Incentive Plan.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Shake Shack's annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: election of two Class II directors (Robert Lynch and Tristan Walker), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →Organon & Co. held its 2026 Annual Meeting of Stockholders on June 9, 2026, with voting results disclosed for four proposals: election of ten directors, advisory vote on named executive officer compensation, approval of an amended 2021 Incentive Stock Plan increasing authorized shares by 8,000,000, and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Fortive Corporation's June 9, 2026 annual shareholder meeting, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each director nominee and proposal are the core content, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →This Item 5.07 discloses the results of Vertex's Annual Meeting of Stockholders held on June 10, 2026, including the election of three directors (Eric Andersen, David DeStefano, and Christopher Young) and the ratification of Crowe LLP as independent auditor, with specific vote tallies for each matter. The disclosure directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Light & Wonder's June 10, 2026 annual stockholder meeting, including voting tallies for five proposals: election of nine directors, advisory approval of named executive officer compensation, approval of director-CEO equity grants under ASX Listing Rule 10.14, approval of non-employee director compensation limits under ASX Listing Rule 10.17, and ratification of Deloitte & Touche LLP as independent auditor. The detailed voting results (For/Against/Abstain/Broker Non-Votes) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →Ocugen held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. Final vote tallies including For, Against, Abstentions, and Broker Non-Votes were disclosed for each proposal.
View raw filing on EDGAR →Qualys held its annual meeting of stockholders on June 10, 2026, at which shareholders voted on four proposals: election of three Class II directors (Bradford L. Brooks, Wendy M. Pfeiffer, and John A. Zangardi), ratification of Grant Thornton LLP as independent auditor, advisory approval of executive compensation, and approval of the amended 2012 Equity Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes for three proposals: election of ten directors to the Board, ratification of KPMG LLP as independent auditors, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.
View raw filing on EDGAR →Shoe Carnival Inc held its 2026 Annual Meeting of Shareholders on June 10, 2026, with shareholder approval of director elections (Diane E. Randolph and J. Wayne Weaver), an advisory compensation vote, auditor ratification (Deloitte & Touche LLP), and a material amendment to change the company's legal name to Shoe Station Group, Inc., effective June 12, 2026.
View raw filing on EDGAR →Orthofix Medical Inc. held its Annual Meeting of Shareholders on June 10, 2026, with voting results disclosed on four matters: election of ten directors, advisory approval of executive compensation, ratification of Ernst & Young LLP as auditor, and approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan increasing available shares by 1,250,000.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes for two proposals: election of two Class II directors (Rainer Erdtmann and Eric Aguiar) and ratification of Deloitte & Touche LLP as independent auditor. The filing provides detailed vote counts (for, against, abstentions, and broker non-votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Airgain's 2026 Annual Meeting held on June 10, 2026. The filing reports final vote tallies for four proposals: election of two Class I directors (Sims and Chung), ratification of Grant Thornton LLP as auditor, advisory approval of named executive officer compensation, and approval of the amended 2016 Incentive Award Plan. All proposals passed. This is a quintessential Item 5.07 shareholder vote results disclosure, material to investors as it confirms governance and compensation decisions.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte & Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst & Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.
View raw filing on EDGAR →This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Heritage Insurance Holdings' annual meeting of stockholders held on June 10, 2026. The section presents results for four proposals: election of six directors, ratification of Plante & Moran as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. These are routine shareholder meeting outcomes that materially inform investors about governance and board composition.
View raw filing on EDGAR →Alphatec held its June 10, 2026 Annual Meeting of Stockholders, at which shareholders voted on five proposals: election of seven directors, ratification of Deloitte & Touche LLP as auditor, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing reports final voting tallies for three proposals: election of three directors (Chris Cain, Arlene Morris, and Todd Shegog), ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed. This is a material event as it confirms the composition of the board and auditor selection, both of which affect investor assessment of governance and financial oversight.
View raw filing on EDGAR →Shareholders of Universal Health Realty Income Trust voted at the June 10, 2026 Annual Meeting on three proposals: election of two Class I trustees (Alan B. Miller and Robert F. McCadden), a nonbinding advisory vote on named executive officer compensation, and ratification of KPMG, LLP as independent auditor.
View raw filing on EDGAR →Alphabet Inc. held its 2026 Annual Meeting of Shareholders on June 5, 2026, with voting results disclosed for fourteen proposals including director elections (Larry Page, Sergey Brin, Sundar Pichai, and others), ratification of Ernst & Young LLP as auditor, approval of stock plan amendments, advisory vote on executive compensation, and multiple shareholder proposals.
View raw filing on EDGAR →Jade Biosciences held its 2026 Annual Meeting of Stockholders with voting results on the election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Aura Biosciences' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for two proposals: election of two Class II directors (David Johnson and Teresa Marie Bitetti) and ratification of Ernst & Young LLP as the independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are characteristic of Item 5.07 disclosures and are material to investors as they confirm governance decisions and auditor appointment.
View raw filing on EDGAR →Legence Corp. held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on five proposals: election of Class I directors (David Coghlan and Bilal Khan), advisory approval of 2026 named executive officer compensation, frequency of future advisory compensation votes (approved for annual frequency), approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Korro Bio's 2026 annual meeting of stockholders held on June 10, 2026, including: (1) election of two Class I directors (Nessan Bermingham and Rachel Meyers) for three-year terms; (2) non-binding advisory approval of named executive officer compensation; and (3) ratification of Ernst & Young LLP as independent auditor. These are routine but material shareholder vote outcomes that affect board composition and governance.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from Nkarta's June 10, 2026 annual meeting. The filing reports the outcomes of four distinct votes: election of two Class III directors (Ali Behbahani and Zachary Scheiner), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and an advisory vote on the frequency of future compensation votes. These are routine but material governance matters that inform investors of shareholder decisions.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.
View raw filing on EDGAR →This Item 5.07 discloses the results of the Company's June 9, 2026 annual meeting of shareholders, including voting outcomes on three matters: (1) election of six trustees, where all candidates failed to meet the two-thirds vote requirement but will continue in office under Maryland law; (2) ratification of Deloitte & Touche LLP as independent auditor, which passed; and (3) an advisory say-on-pay resolution that was rejected by shareholders. The disclosure of shareholder vote results, particularly the failure of the say-on-pay proposal and the trustee election shortfall, is material to investors assessing governance and compensation practices.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fractyl Health's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Marc Elia, Clive Meanwell, and Ian Sheffield), and (2) ratification of Ernst & Young LLP as independent auditors. All matters were approved. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Chimera Investment Corp's June 10, 2026 annual meeting of stockholders. The filing presents detailed vote tallies for three proposals: election of three Class I Directors (Kevin G. Chavers, Gerard Creagh, and Susan Mills), a non-binding advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a textbook shareholder_vote_results event.
View raw filing on EDGAR →This Item 5.07 discloses the results of Triller Group Inc.'s 2025 annual meeting of shareholders held on June 10, 2026, including voting outcomes on six proposals: election of four directors, ratification of auditors, approval of a reverse stock split (up to 1-for-10), approval of a name change to "Eight Holdings Inc.," approval of a 2026 Equity Incentive Plan with 39.6 million shares reserved, and approval of a PIPE financing of up to $300 million. The shareholder votes on the reverse split, name change, equity plan, and dilutive PIPE financing are material to investors' assessment of the company's capital structure and strategic direction.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of an Annual Meeting of Shareholders held on June 11, 2026, where shareholders voted on two matters: (1) election of five board members with detailed vote tallies for each director, and (2) ratification of BDO USA, P.C. as the independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →Stockholders approved all four proposals at the 2026 Annual Meeting of Stockholders held on June 11, 2026: election of seven directors, advisory approval of named executive officer compensation, approval of the Third Amendment to the 2017 Equity Incentive Plan (increasing shares by 9,000,000), and ratification of Grant Thornton LLP as independent auditor.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Blackbaud's June 10, 2026 annual meeting, covering three proposals: advisory approval of named executive officer compensation, amendment and restatement of the 2016 Equity and Incentive Compensation Plan, and ratification of Ernst & Young LLP as independent auditor. The filing explicitly states the vote tallies for each proposal, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →Inogen held its 2026 Annual Meeting of Stockholders and disclosed complete voting results on five matters: election of Class III directors (Boehnlein and Sahney), ratification of Deloitte & Touche LLP as independent auditor, advisory vote on executive compensation, approval of the Amended and Restated 2023 Equity Incentive Plan with 750,000 additional shares, and a failed amendment to declassify the Board.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Green Plains Inc.'s 2026 annual shareholder meeting held on June 5, 2026. The filing details voting outcomes for four proposals: election of nine directors, approval of an amendment to the 2019 Equity Incentive Plan to increase authorized shares, ratification of KPMG LLP as independent auditors, and an advisory vote on executive compensation. All matters were approved. Shareholder vote results are material to investors as they reflect governance decisions and capital allocation approvals.
View raw filing on EDGAR →FNF held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of four Class III directors, approval of amended articles to implement annual director elections (eliminating the classified board structure over three years with full annual elections beginning at the 2029 Annual Meeting), advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →Veracyte held its Annual Meeting of stockholders and disclosed complete voting results on four proposals: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2023 Equity Incentive Plan increasing the share reserve by 3,500,000 shares. All proposals passed.
View raw filing on EDGAR →NXP held its 2026 Annual General Meeting on June 10, 2026, with shareholders voting on 11 resolutions including adoption of annual accounts, director re-appointments, board authorizations, auditor re-appointment, and executive compensation approvals. Detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each resolution were disclosed.
View raw filing on EDGAR →Shareholders voted on matters at the Annual Meeting held on June 10, 2026, including the election of five directors. The filing reports detailed vote tallies (for/withheld) for each director nominee.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from the Annual Meeting of Shareholders held on June 10, 2026. The filing reports the outcomes of three proposals: election of two directors (Scott Montross and John Paschal), an advisory vote on named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditors. The detailed vote tallies (For, Against, Abstain, Broker Non-votes) for each proposal are the hallmark of shareholder_vote_results disclosures.
View raw filing on EDGAR →